354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 354,395 shares of the company’s stock, valued at approximately $8,686,000. Walleye Capital LLC owned about 0.80% of BioAge Labs at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in shares of BioAge Labs during the 1st quarter worth about $3,746,000. Renaissance Technologies LLC raised its stake in shares of BioAge Labs by 653.2% in the 1st quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after acquiring an additional 120,188 shares in the last quarter. Stempoint Capital LP acquired a new stake in BioAge Labs in the 1st quarter worth approximately $5,923,000. Octagon Capital Advisors LP lifted its holdings in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have commented on BIOA. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Needham & Company LLC reduced their price objective on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a report on Monday, August 3rd. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, BioAge Labs has an average rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Stock Up 1.6%

Shares of NASDAQ:BIOA opened at $10.60 on Friday. The business has a 50 day moving average price of $19.47 and a 200 day moving average price of $18.86. BioAge Labs, Inc. has a twelve month low of $4.38 and a twelve month high of $25.95. The company has a market cap of $486.54 million, a price-to-earnings ratio of -4.45 and a beta of 0.93.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. Analysts anticipate that BioAge Labs, Inc. will post -2.45 EPS for the current year.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.